Introduction: Understanding Obesity and GLP-1 RAs
Obesity is a complex, chronic disease with a high and rising global prevalence [1, 7]. It is influenced by genetic factors and hormonal responses, and significantly increases the risk of various cardiovascular diseases and cardiometabolic conditions [1, 7]. Historically, interventions beyond lifestyle changes for obesity have been underutilized and sometimes stigmatized [7]. However, contemporary management now includes lifestyle modifications, pharmacotherapy, and in severe cases, surgical intervention [7]. Among the newer pharmacotherapies, glucagon-like peptide-1 (GLP-1) receptor agonists have shown promise as effective long-term treatments for obesity [1].
How GLP-1 Receptor Agonists Work
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications that interact with specific receptors in the body. These agents are designed to achieve substantial weight loss and improve cardiometabolic risk factors [1]. While the precise mechanisms are complex, emerging evidence also suggests they may influence reward-related pathways in the brain [2]. This class of drugs, including GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual receptor agonists, represents a significant development in the medical management of obesity [3, 7].
Significant Weight Loss and Improved Body Composition
Clinical trials have demonstrated the effectiveness of GLP-1 receptor agonists in promoting weight loss. For example, liraglutide has been shown to achieve a mean weight loss of 4-7 kg, with over 50% of individuals losing 5% or more of their body weight [1]. Semaglutide, another GLP-1 receptor agonist, has an even greater impact, leading to a mean weight loss of 9-16 kg, and more than 50% of treated individuals achieving 10-15% or more weight loss [1]. Overall, GLP-1 receptor agonist treatment consistently reduces body weight, body mass index (BMI), and waist circumference [5]. Some studies show a mean body weight decrease of approximately 9% at three months [5].
Beyond just reducing overall weight, these medications also positively influence body composition. Treatment with GLP-1 receptor agonists has been found to significantly improve lean mass as a proportion of total weight, with an observed increase of 1.81% [4]. This suggests an improvement in body composition, and this effect could be further amplified with the use of semaglutide [4]. While some lean mass loss can occur with significant weight reduction, the overall improvement in body composition is a notable benefit [4].
Broader Health Benefits
The benefits of GLP-1 receptor agonists extend beyond just weight reduction. These medications are effective in improving various cardiometabolic risk factors associated with obesity [1]. Additionally, emerging research suggests a potential role for GLP-1 receptor agonists in influencing reward-related pathways, which may offer benefits for nicotine addiction and help mitigate weight gain after smoking cessation [2]. This indicates a broader potential for these medications in addressing interconnected health challenges.
Important Considerations and Potential Challenges
While GLP-1 receptor agonists offer significant benefits, there are important factors to consider. Their use can be limited by cost and the potential for adverse effects [3]. Patients should be counseled on managing these effects [3]. Another challenge is the potential for weight regain if treatment is discontinued [3]. Therefore, ongoing lifestyle modifications, including diet and exercise, remain crucial to maximize and maintain weight loss [3, 7].
Adherence to treatment is also a key factor. While treatment persistence can sometimes be limited by adverse drug reactions [8], a systematic review and meta-analysis of randomized controlled trials found that nonadherence to GLP-1 receptor agonists was 37% lower compared to placebo [8]. This suggests that, in a controlled trial setting, patients on GLP-1 RAs were less likely to discontinue treatment than those on placebo.
For women of childbearing potential, counseling on pregnancy prevention is essential while using these medications [3]. When considering treatment options, it's also worth noting that both metabolic and bariatric surgery (MBS) and GLP-1 receptor agonists are effective strategies for obesity management, and their comparative efficacy is an ongoing area of study [6].
Conclusion: A Promising Tool in Obesity Management
Glucagon-like peptide-1 receptor agonists represent a significant advancement in the pharmacotherapy of obesity [7]. They offer substantial weight loss, improve body composition, and address associated cardiometabolic risks [1, 4, 5]. As part of a comprehensive approach that includes lifestyle modifications, these medications can be a powerful tool in managing obesity as a chronic disease [3, 7]. Patients considering these treatments should have a thorough discussion with their healthcare provider to understand the benefits, risks, and appropriate use.
Sources
[1] Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management. (Current atherosclerosis reports, 2022) https://pubmed.ncbi.nlm.nih.gov/35624390/
[2] GLP-1 agonists for smoking cessation and post-cessation weight management: A systematic review and meta-analysis of randomized trials. (Tobacco induced diseases, 2026) https://pubmed.ncbi.nlm.nih.gov/42529623/
[3] Clinical Considerations in the Use of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management. (Nursing for women's health, 2026) https://pubmed.ncbi.nlm.nih.gov/41453400/
[4] Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs). (International journal of obesity (2005), 2026) https://pubmed.ncbi.nlm.nih.gov/42321502/
[5] GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis. (International journal of obesity (2005), 2026) https://pubmed.ncbi.nlm.nih.gov/42034831/
[6] Metabolic Bariatric Surgery versus GLP-1 Receptor Agonists for Obesity Management: A Systematic Review and Meta-Analysis. (Obesity surgery, 2026) https://pubmed.ncbi.nlm.nih.gov/41826529/
[7] Pharmacotherapy for obesity management-Emphasizing the role of GLP-1 receptor agonist-based therapeutics. (Journal of clinical lipidology, 2026) https://pubmed.ncbi.nlm.nih.gov/41708216/
[8] Nonadherence to GLP-1 Receptor Agonists Among Individuals With Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (Obesity reviews : an official journal of the International Association for the Study of Obesity, 2026) https://pubmed.ncbi.nlm.nih.gov/42503568/